2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

101. Red Cells and Erythropoiesis, Excluding Iron: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Treatment Considerations, Supportive Care, Biological Therapies, Antibody Therapy, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Computer Vision, Deep Learning, Biological Processes, Apoptosis, Pathogenesis, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Quality of Care, Diseases, Bleeding and Clotting, Thromboembolism, Thrombotic Disorders, Bone Marrow Failure Syndromes, Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Immunology, Autoimmune Disorders, Autoimmune Hemolytic Anemia, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult, Pediatric, Neonatal
PAPER

2864 Whole-genome sequencing in rare inherited anemias: A nationwide study

Armin P. Piehler, MD, Lea Dewi Schlieben, PhD2, Stephan Hutter, PhD3, Nicola Goetz, PhD4, Andreas Zoebisch, PhD5, Laura Distelmaier, MD6, Holger Cario7, Torsten Haferlach, MD, PhD8, Wolfgang Kern, MD, PhD9, Manja Meggendorfer, PhD10
1 MLL Munich Leukemia Laboratory, Munich, Germany
2 MLL Munich Leukemia Laboratory, Munich, Germany
3 MLL Munich Leukemia Laboratory, Munich, Germany
4 MLL Munich Leukemia Laboratory, Munich, Germany
5 MLL Munich Leukemia Laboratory, Munich, Germany
6 LMU University Hospital Munich, Munich, Germany
7 Ulm University Medical Center, Ulm, Germany
8 MLL Munich Leukemia Laboratory, Munich, Germany
9 MLL Munich Leukemia Laboratory, Munich, Germany
10 MLL Munich Leukemia Laboratory, Munich, Germany

Introduction:
Hereditary anemias constitute a heterogeneous group of disorders resulting from pathogenic variants in genes that participate in diverse pathophysiological pathways. After exclusion of common causes such as hemoglobinopathies, hereditary spherocytosis, and the most frequent enzymopathies, the etiology remains unresolved in up to 75% of cases despite extensive diagnostic workup. Yet, a genetic diagnosis is essential for accurate classification, clinical management, and genetic counseling. This study evaluates whole-genome sequencing (WGS) for comprehensive, unbiased variant detection to improve diagnostic yield and patient management.

Methods:
Within a national genomics network for hematologic disorders, patients with suspected hereditary anemia were recruited between July 2025 and July 2026. Prior to inclusion, hemoglobinopathies, hereditary spherocytosis, and common enzymopathies were excluded by the referring physician or in-house. Subsequently, patients with unexplained anemia underwent WGS (Illumina NovaSeq 6000, 30x coverage, paired-end 150 bp). Libraries were prepared using the TruSeq DNA PCR-Free kit. Sequence data were analyzed using the DRAGEN pipeline for alignment and variant calling against the hg19 reference genome. Variants including SNVs, indels, and copy-number variants were interpreted according to ACMG recommendations in the context of the clinical phenotype.

Results:
WGS established a molecular diagnosis in 46% (23/50) of patients with previously unexplained anemia. Among the solved cases, disease-causing variants comprised 13 heterozygous, five homozygous, and four compound heterozygous genotypes. At the variant level, 12 distinct missense variants, 10 loss-of-function variants, one deep intronic variant, and one large structural deletion were identified. Diagnoses comprised classical hereditary hemolytic anemia genes, including membrane disorders (e.g., ANK1, KCNN4, PIEZO1, SLC4A1, SPTA1) and red cell enzymopathies (e.g., GPI, HK1, PKLR). Also less expected etiologies such as congenital dyserythropoietic anemia (SEC23B), ribosomopathies (RPS17, RPL35A), and X-linked sideroblastic anemia (ALAS2) were detected.

Importantly, WGS established genetic diagnoses in cases that remained unresolved by conventional laboratory testing. Three out of five genetically confirmed membrane disorder cases had negative Eosin-5-Maleimide (EMA)-binding test results, whereas a patient with SEC23B-associated congenital dyserythropoietic anemia had a positive EMA test result. Moreover, two patients with normal enzyme activity in previous biochemical testing had PK deficiency with respective pathogenic variants in the PKLR gene. These findings highlight the added diagnostic value of WGS beyond routine phenotypic assays.

WGS also revealed diagnoses with further clinical implications beyond hemolytic anemia, such as Wilson disease due to biallelic ATP7B variants in a patient presenting with intermittent hemolysis, macrocytic hyperchromic anemia, and marked reticulocytosis. Furthermore, a syndromic case with ataxia was associated with a likely pathogenic variant in RYR1.

Conclusion:
WGS provided a molecular diagnosis in half of patients remaining unsolved after extensive conventional testing and proved feasible in routine diagnostics. Beyond identifying structural variants and unexpected genetic etiologies inaccessible to targeted approaches, WGS provides a molecular diagnosis that may inform disease-specific management, surveillance, and genetic counselling. These findings support integration of WGS as a comprehensive first-line genomic test following exclusion of common hereditary anemias.

Armin P. Piehler, MD: MLL Munich Leukemia Laboratory - Current Employment